HSBC Holdings
CRSP icon

HSBC Holdings’s CRISPR Therapeutics CRSP Stock Holding History

HSBC Holdings’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-23,100
Closed -$1.08M – 2982
2026
Q1 		$1.08M Buy
23,100
+17,900
+344% +$944K ﹤0.01% 1830
2025
Q4 		$274K Buy
+5,200
New +$311K ﹤0.01% 2564
2021
Q2 		– Sell
-13,300
Closed -$1.62M – 2951
2021
Q1 		$1.62M Buy
+13,300
New +$2.01M ﹤0.01% 1380

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

HSBC Holdings's CRSP Position: Q2 2026 in Review

HSBC Holdings sold out of CRISPR Therapeutics (CRSP) in Q2 2026, closing a stake of 2,787 shares — an estimated $131K sold.

HSBC Holdings first reported a position in CRSP in Q1 2020 and held it in 17 quarters. The position peaked at $1.82M in Q2 2021. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • HSBC Holdings reported no remaining CRISPR Therapeutics position as of Q2 2026 after selling out during the quarter.
  • HSBC Holdings sold 2,787 CRISPR Therapeutics shares in Q2 2026, an estimated $131K.
  • HSBC Holdings first reported a position in CRISPR Therapeutics in Q1 2020 and held it in 17 quarters.
  • HSBC Holdings's CRISPR Therapeutics position peaked at $1.82M in Q2 2021.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on HSBC Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.